Printer Friendly

Cellular Dynamics International Launches Cell Therapies Unit Called Opsis Therapeutics.

M2 EQUITYBITES-September 28, 2016-Cellular Dynamics International Launches Cell Therapies Unit Called Opsis Therapeutics


28 September 2016 - US-based pluripotent stem cell products developer Cellular Dynamics International, Inc. has launched a new venture called Opsis Therapeutics, the company said on Wednesday.

Formed over the summer, Opsis Therapeutics is focused on discovering and developing novel medicines to treat patients suffering from retinal diseases.

The Opsis Therapeutics team brings expertise and a track record of developing technologies and building next-generation cell therapeutic programmes.

This venture has been founded in partnership with David Gamm, M.D., Ph.D., a pioneer in the differentiation and transplantation of iPSC-derived retinal cells.

Opsis Therapeutics will bring together a cross-disciplinary team of advisors and development partners with combined expertise in iPSC manufacture, iPSC differentiation into retinal lineages, retinal cell biology, preclinical modeling of retinal disease, and sub-retinal surgery.

The company is developing new approaches to treating retinal diseases and their associated vision loss, and developing a pipeline of therapeutic candidates.

CDI made the initial seed investment in Opsis Therapeutics, and additional investment will be made as needed for full-scale development.

Therapeutic candidates will be developed in conjunction with CDI's world-leading position in human leukocyte antigen "haplobanking," which enables the therapeutic cells to be matched to the patient's immune system, potentially avoiding the need to co-administer immune suppressing drugs.

In addition, Opsis Therapeutics will benefit from CDI's track record of successful development of cells for ultimate therapeutics use, such as the company's ongoing contract with the National Eye Institute to manufacture clinically compatible iPSC-derived human retinal pigment epithelial cells.

((Comments on this story may be sent to

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Sep 28, 2016
Previous Article:EasyHotel Closes Ipswich Freehold Acquisition.
Next Article:Moberg Pharma announces start of patient enrolment in North America and Europe in two Phase 3 studies of MOB-015 in onychomycosis.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters